Sermorelin discontinuation in the US — what actually happened?

The branded pediatric product (Geref) was pulled from the US market years ago. The compound itself wasn't withdrawn for safety or efficacy — it was a commercial decision.

The FDA approval pathway is still technically open if a manufacturer wanted to reintroduce it. But the market is small and recombinant GH is the entrenched alternative. Compounded sermorelin remains the practical option.